Print
Save
Email this link

Share Link

Copy this link, or click below to email it to a friend
Email this link
or copy the link directly:

https://ec.bioscientifica.com/search?access=user&pageSize=10&q=corticosteroids&sort=relevance&t=EC-Hormones-and-Cancer
The link was not copied. Your current browser may not support copying via this button.

Link copied successfully

Search Results

You are looking at 1 - 2 of 2 items for :

corticosteroids x

Hormones and Cancer x

Clear All

Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer

Ruth Percik

Ruth Percik Institute of Endocrinology, Diabetes and Metabolism, Sheba Medical Centre, Ramat Gan, Israel

Search for other papers by Ruth Percik in
Google Scholar
PubMed

Sherwin Criseno

Sherwin Criseno Department of Endocrinology, University Hospital Birmingham, Birmingham, UK

Search for other papers by Sherwin Criseno in
Google Scholar
PubMed

Safwaan Adam

Safwaan Adam Department of Endocrinology, The Christie NHS Foundation Trust, Manchester, UK

Search for other papers by Safwaan Adam in
Google Scholar
PubMed

Kate Young

Kate Young Royal Marsden Hospital, London, UK

Search for other papers by Kate Young in
Google Scholar
PubMed

, and

Daniel L Morganstein

Daniel L Morganstein Department of Endocrinology, Chelsea and Westminster Hospital, London, UK
Royal Marsden Hospital, London, UK

Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed

glucocorticoids such as creams, inhalers or nasal sprays, including those used for non-ICPI-related toxicity (e.g. asthma). Where potentially suppressive doses of corticosteroids have been used ( 27 ), a careful weaning protocol should be followed (such as that in

Article Type:: Review Article

Collections:: Hormones and Cancer

DOI:: https://doi.org/10.1530/EC-22-0513

Volume/Issue:: Volume 12: Issue 5

Open access

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma

Hanna Karhapää

Hanna Karhapää Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland

Search for other papers by Hanna Karhapää in
Google Scholar
PubMed

Siru Mäkelä

Siru Mäkelä Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland

Search for other papers by Siru Mäkelä in
Google Scholar
PubMed

Hanna Laurén

Hanna Laurén Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Search for other papers by Hanna Laurén in
Google Scholar
PubMed

Marjut Jaakkola

Marjut Jaakkola Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Search for other papers by Marjut Jaakkola in
Google Scholar
PubMed

Camilla Schalin-Jäntti

Camilla Schalin-Jäntti Medical Faculty, University of Helsinki, Helsinki, Finland
Endocrinology, Abdominal Centre, University of Helsinki and HUS, Helsinki, Finland

Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed

, and

Micaela Hernberg

Micaela Hernberg Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland

Search for other papers by Micaela Hernberg in
Google Scholar
PubMed

status translating into a generalized ICI-induced immune activation. Earlier, it has been shown that the improved outcome can be maintained despite the use of corticosteroids to treat irAEs ( 32 ). ICI treatment itself and possible endocrine AEs may